Abstract
Antiprogestins represent a new class of promising drugs in fertility regulation, especially in early termination of pregnancy. RU 486 (mifepristone), manufactured by Roussel-Uclaf and marketed under the international trade name Mifegyne, is an antiprogestin tablet that is used sequentially with a prostaglandin for non-surgical termination of pregnancy. It has been chosen as a pregnancy termination method by over 100,000 women in France since its regulatory approval there in 1988. In addition, RU 486/prostaglandin was approved in July 1991 for use in the United Kingdom and an application for approval is being considered in Sweden. In Western Europe, it seems, RU 486/prostaglandin is increasingly accepted by medical experts, regulatory officials and women as an alternative to vacuum aspiration or dilation and curettage (D&C) for early pregnancy termination.As the use of RU 486/prostaglandin becomes more established, health practitioners and women's health advocates are beginning to consider the feasibility of using this method for pregnancy termination in low-resource settings.
Publisher
Cambridge University Press (CUP)
Reference120 articles.
1. 20. Personal Communication, Dr. Étienne-Émile Baulieu, February 3, 1992.
2. 11. Kalra, P.A. et al., “Cardiac Standstill Induced by Prostaglandin Pessaries”, The Lancet (June 24, 1989): 1460–1461.
3. 38. Personal Communication, Dr. Herbert Lawson, supra, note 36.
4. 24. Id.
5. “A Pilot Study of Acceptability of RU 486 and ONO 802 in a Chinese Population”;Tang;Contraception,1991
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献